Ruottinen HM - Search Results

1

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO. Nurmi E, et al. Among authors: ruottinen hm. Mov Disord. 2001 Jul;16(4):608-15. doi: 10.1002/mds.1139. Mov Disord. 2001. PMID: 11481683

2

PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.

Laihinen AO, Rinne JO, Någren KA, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Ruottinen HM, Rinne UK. Laihinen AO, et al. Among authors: ruottinen hm. J Nucl Med. 1995 Jul;36(7):1263-7. J Nucl Med. 1995. PMID: 7790953 Free article.

3

[18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.

Ruottinen HM, Rinne JO, Haaparanta M, Solin O, Bergman J, Oikonen VJ, Järvelä I, Santavuori P. Ruottinen HM, et al. J Neurol Neurosurg Psychiatry. 1997 Jun;62(6):622-5. doi: 10.1136/jnnp.62.6.622. J Neurol Neurosurg Psychiatry. 1997. PMID: 9219750 Free PMC article.

4

Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.

Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK. Ruottinen HM, et al. Synapse. 1997 Dec;27(4):336-46. doi: 10.1002/(SICI)1098-2396(199712)27:4<336::AID-SYN7>3.0.CO;2-D. Synapse. 1997. PMID: 9372556

5

Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.

Ruottinen HM, Rinne JO, Ruotsalainen UH, Bergman JR, Oikonen VJ, Haaparanta MT, Solin OH, Laihinen AO, Rinne UK. Ruottinen HM, et al. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):91-106. doi: 10.1007/BF02251225. J Neural Transm Park Dis Dement Sect. 1995. PMID: 9620057 Clinical Trial.

6

Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.

Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO. Kaasinen V, et al. Among authors: ruottinen hm. J Nucl Med. 2000 Jan;41(1):65-70. J Nucl Med. 2000. PMID: 10647606 Free article.

7

An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome.

Ruottinen HM, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O, Rinne JO. Ruottinen HM, et al. Neurology. 2000 Jan 25;54(2):502-4. doi: 10.1212/wnl.54.2.502. Neurology. 2000. PMID: 10668725

8

Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.

Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO. Nurmi E, et al. Among authors: ruottinen hm. Ann Neurol. 2000 Jun;47(6):804-8. Ann Neurol. 2000. PMID: 10852547

9

Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.

Ruottinen HM, Niinivirta M, Bergman J, Oikonen V, Solin O, Eskola O, Eronen E, Sonninen P, Rinne UK. Ruottinen HM, et al. Synapse. 2001 Apr;40(1):19-26. doi: 10.1002/1098-2396(200104)40:1<19::AID-SYN1022>3.0.CO;2-7. Synapse. 2001. PMID: 11170218

10

[(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.

Rinne OJ, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O. Rinne OJ, et al. Among authors: ruottinen hm. Synapse. 2001 Jun 1;40(3):193-200. doi: 10.1002/syn.1042. Synapse. 2001. PMID: 11304757

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters